CA2536181A1 - Polymer compositions and methods for their use - Google Patents
Polymer compositions and methods for their use Download PDFInfo
- Publication number
- CA2536181A1 CA2536181A1 CA002536181A CA2536181A CA2536181A1 CA 2536181 A1 CA2536181 A1 CA 2536181A1 CA 002536181 A CA002536181 A CA 002536181A CA 2536181 A CA2536181 A CA 2536181A CA 2536181 A1 CA2536181 A1 CA 2536181A1
- Authority
- CA
- Canada
- Prior art keywords
- fibrotic agent
- polymer
- reactants
- agent
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims 1889
- 229920000642 polymer Polymers 0.000 title claims 568
- 239000000203 mixture Substances 0.000 title claims 62
- 239000003795 chemical substances by application Substances 0.000 claims 1183
- 230000003510 anti-fibrotic effect Effects 0.000 claims 1148
- 239000000376 reactant Substances 0.000 claims 516
- 150000001875 compounds Chemical class 0.000 claims 247
- 229960005475 antiinfective agent Drugs 0.000 claims 140
- 239000004599 antimicrobial Substances 0.000 claims 140
- 108010035532 Collagen Proteins 0.000 claims 130
- 102000008186 Collagen Human genes 0.000 claims 130
- 229920001436 collagen Polymers 0.000 claims 130
- 239000003112 inhibitor Substances 0.000 claims 126
- 229920000233 poly(alkylene oxides) Polymers 0.000 claims 68
- 239000005557 antagonist Substances 0.000 claims 56
- 102000004169 proteins and genes Human genes 0.000 claims 56
- 108090000623 proteins and genes Proteins 0.000 claims 56
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims 54
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 52
- 210000001519 tissue Anatomy 0.000 claims 49
- 125000003277 amino group Chemical group 0.000 claims 48
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 48
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 42
- 108010039918 Polylysine Proteins 0.000 claims 28
- 239000003429 antifungal agent Substances 0.000 claims 28
- 230000015572 biosynthetic process Effects 0.000 claims 28
- 229940043355 kinase inhibitor Drugs 0.000 claims 28
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical group COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 claims 28
- 229920000656 polylysine Polymers 0.000 claims 28
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 claims 27
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 claims 27
- 235000014655 lactic acid Nutrition 0.000 claims 26
- 239000004310 lactic acid Substances 0.000 claims 26
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 24
- -1 poly(ethylene glycol) Polymers 0.000 claims 24
- 229920001059 synthetic polymer Polymers 0.000 claims 22
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 21
- 229940123034 Heat shock protein 90 antagonist Drugs 0.000 claims 21
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical group C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 21
- 229940122696 MAP kinase inhibitor Drugs 0.000 claims 21
- 239000000556 agonist Substances 0.000 claims 21
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 claims 21
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 21
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims 21
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims 21
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 claims 21
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 21
- 229960001237 podophyllotoxin Drugs 0.000 claims 21
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 claims 21
- 238000003786 synthesis reaction Methods 0.000 claims 21
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 21
- PGEGFAGJACEMIS-UHFFFAOYSA-N carbon dioxide;pyrrolidine-2,5-dione Chemical group O=C=O.O=C1CCC(=O)N1 PGEGFAGJACEMIS-UHFFFAOYSA-N 0.000 claims 20
- WAVYAFBQOXCGSZ-UHFFFAOYSA-N 2-fluoropyrimidine Chemical group FC1=NC=CC=N1 WAVYAFBQOXCGSZ-UHFFFAOYSA-N 0.000 claims 14
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical group NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 14
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims 14
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 14
- 108010049003 Fibrinogen Proteins 0.000 claims 14
- 102000008946 Fibrinogen Human genes 0.000 claims 14
- 229940122331 Fibrinogen antagonist Drugs 0.000 claims 14
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 14
- 108010010803 Gelatin Proteins 0.000 claims 14
- 229940118547 Guanylate cyclase stimulant Drugs 0.000 claims 14
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical group NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims 14
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical group NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 claims 14
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical group NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 14
- 229940126033 PPAR agonist Drugs 0.000 claims 14
- 229930012538 Paclitaxel Natural products 0.000 claims 14
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 14
- 229940044684 anti-microtubule agent Drugs 0.000 claims 14
- 229920000229 biodegradable polyester Polymers 0.000 claims 14
- 239000004622 biodegradable polyester Substances 0.000 claims 14
- 229940127093 camptothecin Drugs 0.000 claims 14
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical group C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 14
- GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 claims 14
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims 14
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 14
- 229960005420 etoposide Drugs 0.000 claims 14
- 229940012952 fibrinogen Drugs 0.000 claims 14
- 229960002949 fluorouracil Drugs 0.000 claims 14
- 239000004052 folic acid antagonist Substances 0.000 claims 14
- 229920000159 gelatin Polymers 0.000 claims 14
- 239000008273 gelatin Substances 0.000 claims 14
- 235000019322 gelatine Nutrition 0.000 claims 14
- 235000011852 gelatine desserts Nutrition 0.000 claims 14
- 229960001330 hydroxycarbamide Drugs 0.000 claims 14
- 229960001592 paclitaxel Drugs 0.000 claims 14
- 239000002307 peroxisome proliferator activated receptor agonist Substances 0.000 claims 14
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical group [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 14
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 14
- 229960002930 sirolimus Drugs 0.000 claims 14
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 14
- 229960001967 tacrolimus Drugs 0.000 claims 14
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims 14
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 12
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 claims 12
- 229920001223 polyethylene glycol Polymers 0.000 claims 12
- 210000004204 blood vessel Anatomy 0.000 claims 9
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical group O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims 7
- DOEWDSDBFRHVAP-KRXBUXKQSA-N (E)-3-tosylacrylonitrile Chemical group CC1=CC=C(S(=O)(=O)\C=C\C#N)C=C1 DOEWDSDBFRHVAP-KRXBUXKQSA-N 0.000 claims 7
- 101710175516 14 kDa zinc-binding protein Proteins 0.000 claims 7
- YZEUHQHUFTYLPH-UHFFFAOYSA-N 2-nitroimidazole Chemical group [O-][N+](=O)C1=NC=CN1 YZEUHQHUFTYLPH-UHFFFAOYSA-N 0.000 claims 7
- 229940124125 5 Lipoxygenase inhibitor Drugs 0.000 claims 7
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 claims 7
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 claims 7
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical group N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims 7
- 239000005541 ACE inhibitor Substances 0.000 claims 7
- 102000055025 Adenosine deaminases Human genes 0.000 claims 7
- 108010088751 Albumins Proteins 0.000 claims 7
- 102000009027 Albumins Human genes 0.000 claims 7
- 229940122195 Alpha2 integrin antagonist Drugs 0.000 claims 7
- 229940086440 Angiotensin I converting enzyme inhibitor Drugs 0.000 claims 7
- 229940123413 Angiotensin II antagonist Drugs 0.000 claims 7
- 102000000412 Annexin Human genes 0.000 claims 7
- 108050008874 Annexin Proteins 0.000 claims 7
- 108010039627 Aprotinin Proteins 0.000 claims 7
- 229940122361 Bisphosphonate Drugs 0.000 claims 7
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 claims 7
- 229940123003 Cathepsin inhibitor Drugs 0.000 claims 7
- 229940123587 Cell cycle inhibitor Drugs 0.000 claims 7
- 229940122444 Chemokine receptor antagonist Drugs 0.000 claims 7
- 108020004414 DNA Proteins 0.000 claims 7
- 108020005124 DNA Adducts Proteins 0.000 claims 7
- 102000003915 DNA Topoisomerases Human genes 0.000 claims 7
- 108090000323 DNA Topoisomerases Proteins 0.000 claims 7
- 229940126161 DNA alkylating agent Drugs 0.000 claims 7
- 239000012624 DNA alkylating agent Substances 0.000 claims 7
- 230000005778 DNA damage Effects 0.000 claims 7
- 231100000277 DNA damage Toxicity 0.000 claims 7
- 230000002112 DNA intercalation Effects 0.000 claims 7
- 230000006820 DNA synthesis Effects 0.000 claims 7
- 101710088194 Dehydrogenase Proteins 0.000 claims 7
- 229940124186 Dehydrogenase inhibitor Drugs 0.000 claims 7
- 229940122858 Elastase inhibitor Drugs 0.000 claims 7
- 229940118365 Endothelin receptor antagonist Drugs 0.000 claims 7
- 229940122586 Enkephalinase inhibitor Drugs 0.000 claims 7
- 102400001368 Epidermal growth factor Human genes 0.000 claims 7
- 101800003838 Epidermal growth factor Proteins 0.000 claims 7
- 102100029951 Estrogen receptor beta Human genes 0.000 claims 7
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 7
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims 7
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims 7
- 108010054218 Factor VIII Proteins 0.000 claims 7
- 102000001690 Factor VIII Human genes 0.000 claims 7
- 229940123583 Factor Xa inhibitor Drugs 0.000 claims 7
- 229940124226 Farnesyltransferase inhibitor Drugs 0.000 claims 7
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims 7
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims 7
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 claims 7
- 102000003658 Group IV Phospholipases A2 Human genes 0.000 claims 7
- 108010082107 Group IV Phospholipases A2 Proteins 0.000 claims 7
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 claims 7
- 229940122296 IKK2 inhibitor Drugs 0.000 claims 7
- GRSZFWQUAKGDAV-KQYNXXCUSA-N IMP Chemical group O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-KQYNXXCUSA-N 0.000 claims 7
- 229940122355 Insulin sensitizer Drugs 0.000 claims 7
- 102100025306 Integrin alpha-IIb Human genes 0.000 claims 7
- 101710149643 Integrin alpha-IIb Proteins 0.000 claims 7
- 108010008212 Integrin alpha4beta1 Proteins 0.000 claims 7
- 108010002352 Interleukin-1 Proteins 0.000 claims 7
- 108090000978 Interleukin-4 Proteins 0.000 claims 7
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 claims 7
- 229940123313 MCP-1 antagonist Drugs 0.000 claims 7
- 229940124761 MMP inhibitor Drugs 0.000 claims 7
- 102000029749 Microtubule Human genes 0.000 claims 7
- 108091022875 Microtubule Proteins 0.000 claims 7
- RRHONYZEMUNMJX-UHFFFAOYSA-N N-[5-[[5-[(4-acetyl-1-piperazinyl)-oxomethyl]-4-methoxy-2-methylphenyl]thio]-2-thiazolyl]-4-[(3-methylbutan-2-ylamino)methyl]benzamide Chemical group C1=C(C(=O)N2CCN(CC2)C(C)=O)C(OC)=CC(C)=C1SC(S1)=CN=C1NC(=O)C1=CC=C(CNC(C)C(C)C)C=C1 RRHONYZEMUNMJX-UHFFFAOYSA-N 0.000 claims 7
- 229940123134 Nitric oxide inhibitor Drugs 0.000 claims 7
- 229940121682 Osteoclast inhibitor Drugs 0.000 claims 7
- 108091008606 PDGF receptors Proteins 0.000 claims 7
- 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 claims 7
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 claims 7
- 229940121927 Phospholipase A1 inhibitor Drugs 0.000 claims 7
- 102000013566 Plasminogen Human genes 0.000 claims 7
- 108010051456 Plasminogen Proteins 0.000 claims 7
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 claims 7
- 229940120646 Platelet-derived growth factor receptor kinase inhibitor Drugs 0.000 claims 7
- 229940123924 Protein kinase C inhibitor Drugs 0.000 claims 7
- 229940123752 RNA synthesis inhibitor Drugs 0.000 claims 7
- 229940122756 Retinoic acid receptor antagonist Drugs 0.000 claims 7
- 108091028664 Ribonucleotide Proteins 0.000 claims 7
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 7
- 229940123237 Taxane Drugs 0.000 claims 7
- 108090000190 Thrombin Proteins 0.000 claims 7
- 229940122435 VCAM-1 antagonist Drugs 0.000 claims 7
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 7
- 108010034265 Vascular Endothelial Growth Factor Receptors Proteins 0.000 claims 7
- 229940122803 Vinca alkaloid Drugs 0.000 claims 7
- 108010031318 Vitronectin Proteins 0.000 claims 7
- 102100035140 Vitronectin Human genes 0.000 claims 7
- LVBMFPUTQOHXQE-UHFFFAOYSA-N [2-[6-(diaminomethylideneamino)hexylamino]-2-oxoethyl] n-[4-(3-aminopropylamino)butyl]carbamate Chemical group NCCCNCCCCNC(=O)OCC(=O)NCCCCCCN=C(N)N LVBMFPUTQOHXQE-UHFFFAOYSA-N 0.000 claims 7
- 125000005227 alkyl sulfonate group Chemical group 0.000 claims 7
- 230000033115 angiogenesis Effects 0.000 claims 7
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 7
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 7
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 7
- 239000003242 anti bacterial agent Substances 0.000 claims 7
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 7
- 239000002260 anti-inflammatory agent Substances 0.000 claims 7
- 230000000340 anti-metabolite Effects 0.000 claims 7
- 239000003146 anticoagulant agent Substances 0.000 claims 7
- 229940121375 antifungal agent Drugs 0.000 claims 7
- 229940100197 antimetabolite Drugs 0.000 claims 7
- 239000002256 antimetabolite Substances 0.000 claims 7
- 229960004676 antithrombotic agent Drugs 0.000 claims 7
- 230000006907 apoptotic process Effects 0.000 claims 7
- 229960004405 aprotinin Drugs 0.000 claims 7
- AUJRCFUBUPVWSZ-XTZHGVARSA-M auranofin Chemical group CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O AUJRCFUBUPVWSZ-XTZHGVARSA-M 0.000 claims 7
- 229960005207 auranofin Drugs 0.000 claims 7
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical group C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims 7
- 229940092705 beclomethasone Drugs 0.000 claims 7
- 230000003115 biocidal effect Effects 0.000 claims 7
- 229920002988 biodegradable polymer Polymers 0.000 claims 7
- 239000004621 biodegradable polymer Substances 0.000 claims 7
- 150000004663 bisphosphonates Chemical group 0.000 claims 7
- 235000020964 calcitriol Nutrition 0.000 claims 7
- 239000011612 calcitriol Substances 0.000 claims 7
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical group C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 claims 7
- 159000000007 calcium salts Chemical class 0.000 claims 7
- 150000001720 carbohydrates Chemical class 0.000 claims 7
- 235000014633 carbohydrates Nutrition 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 7
- 239000002559 chemokine receptor antagonist Substances 0.000 claims 7
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 7
- 229960004316 cisplatin Drugs 0.000 claims 7
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 claims 7
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical group O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 claims 7
- 230000008021 deposition Effects 0.000 claims 7
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 7
- 229960003957 dexamethasone Drugs 0.000 claims 7
- 102000006795 dihydrofolate reductase activity proteins Human genes 0.000 claims 7
- 108040000939 dihydrofolate reductase activity proteins Proteins 0.000 claims 7
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 7
- 229960004679 doxorubicin Drugs 0.000 claims 7
- 239000003602 elastase inhibitor Substances 0.000 claims 7
- 239000002308 endothelin receptor antagonist Substances 0.000 claims 7
- 239000002792 enkephalinase inhibitor Substances 0.000 claims 7
- 229940116977 epidermal growth factor Drugs 0.000 claims 7
- 102000015694 estrogen receptors Human genes 0.000 claims 7
- 108010038795 estrogen receptors Proteins 0.000 claims 7
- 229960005167 everolimus Drugs 0.000 claims 7
- 210000002744 extracellular matrix Anatomy 0.000 claims 7
- 229960000301 factor viii Drugs 0.000 claims 7
- 210000002950 fibroblast Anatomy 0.000 claims 7
- 229940126864 fibroblast growth factor Drugs 0.000 claims 7
- 230000019305 fibroblast migration Effects 0.000 claims 7
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical group N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 claims 7
- 239000003862 glucocorticoid Substances 0.000 claims 7
- 229960002706 gusperimus Drugs 0.000 claims 7
- IDINUJSAMVOPCM-UHFFFAOYSA-N gusperimus Chemical group NCCCNCCCCNC(=O)C(O)NC(=O)CCCCCCN=C(N)N IDINUJSAMVOPCM-UHFFFAOYSA-N 0.000 claims 7
- 229960001340 histamine Drugs 0.000 claims 7
- 239000003485 histamine H2 receptor antagonist Substances 0.000 claims 7
- 239000003395 histamine H3 receptor antagonist Substances 0.000 claims 7
- 230000003301 hydrolyzing effect Effects 0.000 claims 7
- 230000000774 hypoallergenic effect Effects 0.000 claims 7
- 230000002519 immonomodulatory effect Effects 0.000 claims 7
- 229960003444 immunosuppressant agent Drugs 0.000 claims 7
- 230000001861 immunosuppressant effect Effects 0.000 claims 7
- 239000003018 immunosuppressive agent Substances 0.000 claims 7
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 claims 7
- 235000013902 inosinic acid Nutrition 0.000 claims 7
- 239000012948 isocyanate Substances 0.000 claims 7
- 150000002513 isocyanates Chemical class 0.000 claims 7
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims 7
- 239000003120 macrolide antibiotic agent Substances 0.000 claims 7
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 claims 7
- 229960004961 mechlorethamine Drugs 0.000 claims 7
- 229960000485 methotrexate Drugs 0.000 claims 7
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 claims 7
- 210000004688 microtubule Anatomy 0.000 claims 7
- 229960001156 mitoxantrone Drugs 0.000 claims 7
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical group O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims 7
- 229960000951 mycophenolic acid Drugs 0.000 claims 7
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical group OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 claims 7
- 239000002742 neurokinin 1 receptor antagonist Substances 0.000 claims 7
- 239000002740 neurokinin 3 receptor antagonist Substances 0.000 claims 7
- 229960003966 nicotinamide Drugs 0.000 claims 7
- 235000005152 nicotinamide Nutrition 0.000 claims 7
- 239000011570 nicotinamide Substances 0.000 claims 7
- OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical group NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 claims 7
- 239000002773 nucleotide Substances 0.000 claims 7
- 125000003729 nucleotide group Chemical group 0.000 claims 7
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims 7
- KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical group C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 claims 7
- 229960005330 pimecrolimus Drugs 0.000 claims 7
- 210000002381 plasma Anatomy 0.000 claims 7
- 229910052697 platinum Inorganic materials 0.000 claims 7
- 150000003058 platinum compounds Chemical group 0.000 claims 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 7
- 230000035755 proliferation Effects 0.000 claims 7
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 claims 7
- 239000003881 protein kinase C inhibitor Substances 0.000 claims 7
- 239000003909 protein kinase inhibitor Substances 0.000 claims 7
- 238000001243 protein synthesis Methods 0.000 claims 7
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims 7
- 230000006824 pyrimidine synthesis Effects 0.000 claims 7
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 7
- 229940044551 receptor antagonist Drugs 0.000 claims 7
- 239000002464 receptor antagonist Substances 0.000 claims 7
- 230000008929 regeneration Effects 0.000 claims 7
- 238000011069 regeneration method Methods 0.000 claims 7
- 102000000568 rho-Associated Kinases Human genes 0.000 claims 7
- 108010041788 rho-Associated Kinases Proteins 0.000 claims 7
- 239000002336 ribonucleotide Substances 0.000 claims 7
- 125000002652 ribonucleotide group Chemical group 0.000 claims 7
- 239000011435 rock Substances 0.000 claims 7
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 7
- 229960002855 simvastatin Drugs 0.000 claims 7
- 150000003431 steroids Chemical class 0.000 claims 7
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 7
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical group C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 7
- 150000003573 thiols Chemical class 0.000 claims 7
- 229960004072 thrombin Drugs 0.000 claims 7
- 239000003769 thromboxane A2 receptor blocking agent Substances 0.000 claims 7
- 230000007838 tissue remodeling Effects 0.000 claims 7
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims 7
- 230000014616 translation Effects 0.000 claims 7
- 229950007229 tresperimus Drugs 0.000 claims 7
- 239000002447 tumor necrosis factor alpha converting enzyme inhibitor Substances 0.000 claims 7
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims 7
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 claims 7
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 7
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 7
- 150000004917 tyrosine kinase inhibitor derivatives Chemical group 0.000 claims 7
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical group C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims 7
- CGTADGCBEXYWNE-JUKNQOCSSA-N zotarolimus Chemical group N1([C@H]2CC[C@@H](C[C@@H](C)[C@H]3OC(=O)[C@@H]4CCCCN4C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@@H](/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C3)OC)C[C@H]2OC)C=NN=N1 CGTADGCBEXYWNE-JUKNQOCSSA-N 0.000 claims 7
- 229950009819 zotarolimus Drugs 0.000 claims 7
- 210000001367 artery Anatomy 0.000 claims 6
- 239000003086 colorant Substances 0.000 claims 6
- 229920002674 hyaluronan Polymers 0.000 claims 6
- 229960003160 hyaluronic acid Drugs 0.000 claims 6
- 230000000269 nucleophilic effect Effects 0.000 claims 6
- 230000008878 coupling Effects 0.000 claims 5
- 238000010168 coupling process Methods 0.000 claims 5
- 238000005859 coupling reaction Methods 0.000 claims 5
- 230000002792 vascular Effects 0.000 claims 5
- 210000004392 genitalia Anatomy 0.000 claims 4
- 239000007943 implant Substances 0.000 claims 4
- 230000002485 urinary effect Effects 0.000 claims 4
- 210000003462 vein Anatomy 0.000 claims 4
- 210000002388 eustachian tube Anatomy 0.000 claims 3
- 230000002496 gastric effect Effects 0.000 claims 3
- 239000000463 material Substances 0.000 claims 3
- 230000003872 anastomosis Effects 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 238000009423 ventilation Methods 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000000560 biocompatible material Substances 0.000 claims 1
- 230000017531 blood circulation Effects 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 230000000112 colonic effect Effects 0.000 claims 1
- 238000004891 communication Methods 0.000 claims 1
- 210000004351 coronary vessel Anatomy 0.000 claims 1
- 238000013461 design Methods 0.000 claims 1
- 238000000502 dialysis Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000013536 elastomeric material Substances 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 210000003709 heart valve Anatomy 0.000 claims 1
- 230000007246 mechanism Effects 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 229910001092 metal group alloy Inorganic materials 0.000 claims 1
- 238000012806 monitoring device Methods 0.000 claims 1
- 210000003101 oviduct Anatomy 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 210000004872 soft tissue Anatomy 0.000 claims 1
- 230000002620 ureteric effect Effects 0.000 claims 1
- 210000001631 vena cava inferior Anatomy 0.000 claims 1
- 230000002861 ventricular Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Surgery (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
- Prostheses (AREA)
- External Artificial Organs (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52390803P | 2003-11-20 | 2003-11-20 | |
| US60/523,908 | 2003-11-20 | ||
| US52522603P | 2003-11-24 | 2003-11-24 | |
| US60/525,226 | 2003-11-24 | ||
| US52654103P | 2003-12-03 | 2003-12-03 | |
| US60/526,541 | 2003-12-03 | ||
| US56656904P | 2004-04-28 | 2004-04-28 | |
| US60/566,569 | 2004-04-28 | ||
| US58686104P | 2004-07-09 | 2004-07-09 | |
| US60/586,861 | 2004-07-09 | ||
| US61107704P | 2004-09-17 | 2004-09-17 | |
| US60/611,077 | 2004-09-17 | ||
| US10/986,231 | 2004-11-10 | ||
| US10/986,231 US20050181977A1 (en) | 2003-11-10 | 2004-11-10 | Medical implants and anti-scarring agents |
| PCT/US2004/039389 WO2005051452A2 (en) | 2003-11-20 | 2004-11-22 | Polymer compositions and methods for their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2536181A1 true CA2536181A1 (en) | 2005-06-09 |
Family
ID=34637499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002536181A Abandoned CA2536181A1 (en) | 2003-11-20 | 2004-11-22 | Polymer compositions and methods for their use |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1684819A2 (enExample) |
| JP (1) | JP2007517543A (enExample) |
| AU (1) | AU2004293071A1 (enExample) |
| CA (1) | CA2536181A1 (enExample) |
| IL (1) | IL174641A0 (enExample) |
| WO (2) | WO2005051452A2 (enExample) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2428354T3 (es) | 2002-09-18 | 2013-11-07 | Trustees Of The University Of Pennsylvania | Rapamicina para usar en la inhibición o prevención de la neovascularización coroidea |
| CN1882338A (zh) | 2003-09-18 | 2006-12-20 | 马库赛特公司 | 经巩膜递送 |
| WO2005049105A2 (en) * | 2003-11-10 | 2005-06-02 | Angiotech International Ag | Medical implants and anti-scarring agents |
| US8663639B2 (en) | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
| JP4974903B2 (ja) | 2005-02-09 | 2012-07-11 | 参天製薬株式会社 | 疾患または状態を処置するための液体処方物 |
| EP1894582A1 (en) * | 2005-06-24 | 2008-03-05 | Tokyo Medical and Dental University | Method for control of drug elution rate and composition for coating of drug-eluting stent |
| JP2007135965A (ja) * | 2005-11-21 | 2007-06-07 | Tohoku Univ | 体内留置多機能ステントおよびその製造方法 |
| JP5528708B2 (ja) | 2006-02-09 | 2014-06-25 | 参天製薬株式会社 | 安定な製剤ならびにそれらを調製および使用する方法 |
| JP5506378B2 (ja) | 2006-03-23 | 2014-05-28 | 参天製薬株式会社 | 血管透過性に関連する疾患または病気のための製剤および方法 |
| EP3047860B1 (en) | 2006-07-20 | 2024-08-28 | OrbusNeich Medical Pte. Ltd. | Bioabsorbable polymeric composition for a medical device |
| US8691321B2 (en) | 2006-10-20 | 2014-04-08 | Orbusneich Medical, Inc. | Bioabsorbable polymeric composition and medical device background |
| US7959942B2 (en) | 2006-10-20 | 2011-06-14 | Orbusneich Medical, Inc. | Bioabsorbable medical device with coating |
| US9023114B2 (en) | 2006-11-06 | 2015-05-05 | Tyrx, Inc. | Resorbable pouches for implantable medical devices |
| WO2008136856A2 (en) * | 2006-11-06 | 2008-11-13 | Tyrx Pharma, Inc. | Resorbable pouches for implantable medical devices |
| US7801624B1 (en) | 2007-01-16 | 2010-09-21 | Pacesetter, Inc. | Reduced perforation distal tip for an implantable cardiac electrotherapy lead |
| US10716528B2 (en) | 2007-03-08 | 2020-07-21 | Sync-Rx, Ltd. | Automatic display of previously-acquired endoluminal images |
| US8542900B2 (en) | 2007-03-08 | 2013-09-24 | Sync-Rx Ltd. | Automatic reduction of interfering elements from an image stream of a moving organ |
| US11197651B2 (en) | 2007-03-08 | 2021-12-14 | Sync-Rx, Ltd. | Identification and presentation of device-to-vessel relative motion |
| US9968256B2 (en) | 2007-03-08 | 2018-05-15 | Sync-Rx Ltd. | Automatic identification of a tool |
| US8700130B2 (en) | 2007-03-08 | 2014-04-15 | Sync-Rx, Ltd. | Stepwise advancement of a medical tool |
| JP5639764B2 (ja) | 2007-03-08 | 2014-12-10 | シンク−アールエックス，リミティド | 運動する器官と共に使用するイメージング及びツール |
| US9629571B2 (en) | 2007-03-08 | 2017-04-25 | Sync-Rx, Ltd. | Co-use of endoluminal data and extraluminal imaging |
| US11064964B2 (en) | 2007-03-08 | 2021-07-20 | Sync-Rx, Ltd | Determining a characteristic of a lumen by measuring velocity of a contrast agent |
| US9375164B2 (en) | 2007-03-08 | 2016-06-28 | Sync-Rx, Ltd. | Co-use of endoluminal data and extraluminal imaging |
| WO2009018546A1 (en) * | 2007-08-02 | 2009-02-05 | Medicis Pharmaceutical Corporation | Method of applying an injectable filler |
| EP2313122B1 (en) * | 2008-07-17 | 2019-03-06 | Micell Technologies, Inc. | Drug delivery medical device |
| US8039433B2 (en) * | 2008-08-19 | 2011-10-18 | Warsaw Orthopedic, Inc. | Osteogenic compositions containing a coloring agent |
| US9144394B2 (en) | 2008-11-18 | 2015-09-29 | Sync-Rx, Ltd. | Apparatus and methods for determining a plurality of local calibration factors for an image |
| US10362962B2 (en) | 2008-11-18 | 2019-07-30 | Synx-Rx, Ltd. | Accounting for skipped imaging locations during movement of an endoluminal imaging probe |
| US9101286B2 (en) | 2008-11-18 | 2015-08-11 | Sync-Rx, Ltd. | Apparatus and methods for determining a dimension of a portion of a stack of endoluminal data points |
| US11064903B2 (en) | 2008-11-18 | 2021-07-20 | Sync-Rx, Ltd | Apparatus and methods for mapping a sequence of images to a roadmap image |
| US8855744B2 (en) | 2008-11-18 | 2014-10-07 | Sync-Rx, Ltd. | Displaying a device within an endoluminal image stack |
| US9974509B2 (en) | 2008-11-18 | 2018-05-22 | Sync-Rx Ltd. | Image super enhancement |
| US9095313B2 (en) | 2008-11-18 | 2015-08-04 | Sync-Rx, Ltd. | Accounting for non-uniform longitudinal motion during movement of an endoluminal imaging probe |
| HUP1000385A2 (en) | 2010-07-21 | 2012-01-30 | Medicontur Orvostechnikai Kft | Alkane diol derivatives preparation thereof and based on them |
| US8895291B2 (en) | 2010-10-08 | 2014-11-25 | Terumo Bct, Inc. | Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions |
| EP2699274B1 (en) | 2011-04-20 | 2015-03-04 | Carbylan Therapeutics, Inc. | In-situ gel forming compositions |
| EP2723231A4 (en) | 2011-06-23 | 2015-02-25 | Sync Rx Ltd | LUMINAL BACKGROUND CLEANING |
| US10307292B2 (en) | 2011-07-18 | 2019-06-04 | Mor Research Applications Ltd | Device for adjusting the intraocular pressure |
| AU2012328415B2 (en) * | 2011-10-28 | 2016-03-17 | Baxter Healthcare Sa | Nonaqueous compositions for bone hemostasis, and methods for their use and manufacture |
| EP2863802B1 (en) | 2012-06-26 | 2020-11-04 | Sync-RX, Ltd. | Flow-related image processing in luminal organs |
| BR112015025904A2 (pt) * | 2013-04-10 | 2017-07-25 | Univ Melbourne | polímero em rede de poliéter biodegradável, substrato, sustentação, película nanoporosa, e, processo para preparar um polímero em rede de poliéter biodegradável |
| CN105793411B (zh) | 2013-11-16 | 2018-04-17 | 泰尔茂比司特公司 | 生物反应器中的细胞扩增 |
| WO2015148704A1 (en) | 2014-03-25 | 2015-10-01 | Terumo Bct, Inc. | Passive replacement of media |
| WO2016049421A1 (en) | 2014-09-26 | 2016-03-31 | Terumo Bct, Inc. | Scheduled feed |
| WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
| WO2017205667A1 (en) | 2016-05-25 | 2017-11-30 | Terumo Bct, Inc. | Cell expansion |
| US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
| US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
| US11096781B2 (en) | 2016-08-01 | 2021-08-24 | Edwards Lifesciences Corporation | Prosthetic heart valve |
| US12234441B2 (en) | 2017-03-31 | 2025-02-25 | Terumo Bct, Inc. | Cell expansion |
| US11624046B2 (en) | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
| US11629332B2 (en) | 2017-03-31 | 2023-04-18 | Terumo Bct, Inc. | Cell expansion |
| CN108498905B (zh) * | 2018-04-03 | 2024-08-06 | 广州迈普再生医学科技股份有限公司 | 用于双联混合注射器的腔镜型喷头及腔镜型双联混合注射器 |
| US11406525B2 (en) | 2017-11-09 | 2022-08-09 | 11 Health And Technologies Limited | Ostomy monitoring system and method |
| ES2997248T3 (en) * | 2018-08-09 | 2025-02-14 | Gambro Lundia Ab | Method for detection of flow obstruction in an extracorporeal circuit, apparatus and computer program |
| USD893514S1 (en) | 2018-11-08 | 2020-08-18 | 11 Health And Technologies Limited | Display screen or portion thereof with graphical user interface |
| US20200254103A1 (en) * | 2019-02-11 | 2020-08-13 | John Mee | Method for treating neurological conditions and improving human cognition |
| CN121242776A (zh) | 2020-08-24 | 2026-01-02 | 爱德华兹生命科学公司 | 用于可扩展假体心脏瓣膜的递送设备的球囊覆盖物 |
| EP4228563A1 (en) | 2020-10-15 | 2023-08-23 | ConvaTec Technologies Inc. | Ostomy systems and methods |
| GB2619893A (en) | 2021-03-23 | 2023-12-20 | Terumo Bct Inc | Cell capture and expansion |
| CN113281317B (zh) * | 2021-05-14 | 2022-04-29 | 北京指真生物科技有限公司 | 一种含有花菁类化合物的编码微球及其制备方法和应用 |
| US12152699B2 (en) | 2022-02-28 | 2024-11-26 | Terumo Bct, Inc. | Multiple-tube pinch valve assembly |
| USD1099116S1 (en) | 2022-09-01 | 2025-10-21 | Terumo Bct, Inc. | Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device |
| CN115382028A (zh) * | 2022-09-19 | 2022-11-25 | 郑州大学第一附属医院 | 一种可降解吻合器材料及其制备方法和应用 |
| WO2024159015A1 (en) * | 2023-01-25 | 2024-08-02 | North Carolina State University | Compositions and methods relating to inhalable therapeutic compositions |
| JP7602090B1 (ja) * | 2024-06-10 | 2024-12-17 | 真由美 大石 | 生体組織の瘢痕化を抑制するための創傷用足場材 |
| CN118903564B (zh) * | 2024-09-02 | 2025-11-04 | 嘉兴睿清医疗科技有限公司 | 一种羟基磷灰石复合聚酯微球及其制备方法和应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6730313B2 (en) * | 2000-01-25 | 2004-05-04 | Edwards Lifesciences Corporation | Delivery systems for periadventitial delivery for treatment of restenosis and anastomotic intimal hyperplasia |
| JP2004529934A (ja) * | 2001-05-01 | 2004-09-30 | アンジオテック ファーマシューティカルズ，インコーポレイテッド | 抗微小管剤およびポリペプチドまたはポリサッカリドを含む組成物、ならびに炎症状態を処置するための医薬品の調製のためのそれらの組成物の使用 |
| US20030207907A1 (en) * | 2002-05-03 | 2003-11-06 | Iversen Patrick L. | Delivery of microparticle-conjugated drugs for inhibition of stenosis |
| US20050208095A1 (en) * | 2003-11-20 | 2005-09-22 | Angiotech International Ag | Polymer compositions and methods for their use |
-
2004
- 2004-11-22 JP JP2006541670A patent/JP2007517543A/ja active Pending
- 2004-11-22 CA CA002536181A patent/CA2536181A1/en not_active Abandoned
- 2004-11-22 EP EP04816983A patent/EP1684819A2/en not_active Withdrawn
- 2004-11-22 WO PCT/US2004/039389 patent/WO2005051452A2/en not_active Ceased
- 2004-11-22 AU AU2004293071A patent/AU2004293071A1/en not_active Abandoned
- 2004-11-22 WO PCT/US2004/039491 patent/WO2005051316A2/en not_active Ceased
-
2006
- 2006-03-30 IL IL174641A patent/IL174641A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL174641A0 (en) | 2006-08-20 |
| EP1684819A2 (en) | 2006-08-02 |
| WO2005051316A2 (en) | 2005-06-09 |
| JP2007517543A (ja) | 2007-07-05 |
| WO2005051316A3 (en) | 2010-01-28 |
| AU2004293071A1 (en) | 2005-06-09 |
| WO2005051452A2 (en) | 2005-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2536181A1 (en) | Polymer compositions and methods for their use | |
| US20050152941A1 (en) | Soft tissue implants and anti-scarring agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |
Effective date: 20160420 |